Laparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA)
Primary Purpose
Gastric Cancer
Status
Active
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Open Gastrectomy
Laparoscopic Gastrectomy
Sponsored by
About this trial
This is an interventional treatment trial for Gastric Cancer focused on measuring Gastric cancer, Gastrectomy, Laparoscopy
Eligibility Criteria
Inclusion Criteria:
- Histologically proven adenocarcinoma of the stomach
- Surgically resectable (cT1-4a, N0-3b, M0) tumor
- Age ≥ 18 years
- European Clinical Oncology Group (ECOG) performance status 0, 1 or 2.
- Written informed consent
Exclusion Criteria:
- Siewert type I esophagogastric junction tumor
- Non-elective surgery
- Previous gastric resection or recurrent gastric cancer
- Pregnancy
Sites / Locations
- Zorggroep Twente Almelo
- Meander Medical Center
- VU University Medical Center
- Academic Medical Center
- Gelre Hospital
- Catharina Hospital
- Leiden University Medical Center
- Erasmus Medical Center
- Zuyderland Medical Center
- University Medical Center Utrecht
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Open Gastrectomy
Laparoscopic Gastrectomy
Arm Description
Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy.
Outcomes
Primary Outcome Measures
Post-operative hospital stay
The primary outcome of this study is the post-operative hospital stay (days), since this is considered a strong end point as it reflects the impact of the different surgical procedures.
Secondary Outcome Measures
Mortality
Measured as 30-day mortality rate
Post-operative morbidity
Complications will be classified according to the Clavien-Dindo system and include anastomotic leakage, anastomotic stricture, respiratory complications, cardiac complications, intra-abdominal bleeding , intra-abdominal abscess, sepsis, ileus, wound infection, fistula, urinary tract infection and dumping syndrome
Cost-effectiveness
Cost-effectiveness will be calculated by comparing the direct medical cost related to both strategies up until five years after the operation
Quality of Life
The validated quality of life questionnaires EORTC QLQ-30, EORTC QLQ-STO22 and EQ-5D-5L, will be filled in pre-operative <5 days and post-operative at 6 weeks, 12, 24, 36, 48 and 60 months after surgery.
Readmissions
The number of post-operative readmissions
Oncologic outcomes (R0-resection rate and lymph node yield)
R0-resection rate of the distal and proximal margin, defined according to the College of American Pathologists. Lymph node yield: the amount of harvested lymph nodes per patient.
Full Information
NCT ID
NCT02248519
First Posted
September 17, 2014
Last Updated
September 2, 2020
Sponsor
UMC Utrecht
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development, Johnson & Johnson
1. Study Identification
Unique Protocol Identification Number
NCT02248519
Brief Title
Laparoscopic Versus Open Gastrectomy for Gastric Cancer
Acronym
LOGICA
Official Title
Laparoscopic Versus Open Gastrectomy for Gastric Cancer, a Multicenter Prospectively Randomized Controlled Trial (LOGICA-trial)
Study Type
Interventional
2. Study Status
Record Verification Date
September 2020
Overall Recruitment Status
Active, not recruiting
Study Start Date
December 2014 (Actual)
Primary Completion Date
November 2018 (Actual)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
UMC Utrecht
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development, Johnson & Johnson
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is the first randomized controlled trial comparing laparoscopic and open gastrectomy for resectable gastric cancer in a Western population. The hypothesis is that laparoscopic gastrectomy will result in a lower post-operative burden by means of shorter post-operative hospital stay. Secondarily that laparoscopic gastrectomy is hypothesized to be associated with lower post-operative morbidity and readmissions, higher cost-effectiveness, and better post-operative quality of life, with similar mortality and oncologic outcomes, compared to open gastrectomy. The study starts on 1 December 2014. Inclusion and follow-up will take three and five years respectively. Short-term results will be analyzed and published after discharge of the last randomized patient.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Cancer
Keywords
Gastric cancer, Gastrectomy, Laparoscopy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
210 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Open Gastrectomy
Arm Type
Active Comparator
Arm Description
Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
Arm Title
Laparoscopic Gastrectomy
Arm Type
Experimental
Arm Description
Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy.
Intervention Type
Procedure
Intervention Name(s)
Open Gastrectomy
Intervention Description
Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
Intervention Type
Procedure
Intervention Name(s)
Laparoscopic Gastrectomy
Intervention Description
Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy. If laparoscopic resection does not seem feasible during surgery, the procedure may be converted to an open gastrectomy.
Primary Outcome Measure Information:
Title
Post-operative hospital stay
Description
The primary outcome of this study is the post-operative hospital stay (days), since this is considered a strong end point as it reflects the impact of the different surgical procedures.
Time Frame
During admission, an expected average of 2 weeks
Secondary Outcome Measure Information:
Title
Mortality
Description
Measured as 30-day mortality rate
Time Frame
30 days post-operative
Title
Post-operative morbidity
Description
Complications will be classified according to the Clavien-Dindo system and include anastomotic leakage, anastomotic stricture, respiratory complications, cardiac complications, intra-abdominal bleeding , intra-abdominal abscess, sepsis, ileus, wound infection, fistula, urinary tract infection and dumping syndrome
Time Frame
Up to 5 years post-operative
Title
Cost-effectiveness
Description
Cost-effectiveness will be calculated by comparing the direct medical cost related to both strategies up until five years after the operation
Time Frame
Up to 5 years post-operative
Title
Quality of Life
Description
The validated quality of life questionnaires EORTC QLQ-30, EORTC QLQ-STO22 and EQ-5D-5L, will be filled in pre-operative <5 days and post-operative at 6 weeks, 12, 24, 36, 48 and 60 months after surgery.
Time Frame
Up to 5 years post-operative
Title
Readmissions
Description
The number of post-operative readmissions
Time Frame
Up to 5 years post-operative
Title
Oncologic outcomes (R0-resection rate and lymph node yield)
Description
R0-resection rate of the distal and proximal margin, defined according to the College of American Pathologists. Lymph node yield: the amount of harvested lymph nodes per patient.
Time Frame
Pathology report 1-2 weeks after surgery
Other Pre-specified Outcome Measures:
Title
Perioperative blood loss
Description
Measured in milliliters (ml)
Time Frame
Post-operative day 1
Title
Operative time
Description
The time from incision to closure of all wounds in minutes (min)
Time Frame
Post-operative day 1
Title
Conversion rate
Description
The percentage (%) of laparoscopic gastrectomies that had to be converted intra-operatively to an open procedure due to any reason.
Time Frame
Post-operative day 1
Title
Survival
Description
Measured as 5-year disease free survival and 5-year overall survival
Time Frame
Up to 5 years post-operative
Title
VAS-score
Time Frame
Post-operative day 1 and 2
Title
Surgeons ergonomics
Description
Measured with the Subjective Mental Effort Questionnaire (SMEQ)
Time Frame
Post-operative day 1
Title
Time to return to normal nutritional regime
Time Frame
Up to 5 years post-operative
Title
Time to return to daily activity
Time Frame
Up to 5 years post-operative
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histologically proven adenocarcinoma of the stomach
Surgically resectable (cT1-4a, N0-3b, M0) tumor
Age ≥ 18 years
European Clinical Oncology Group (ECOG) performance status 0, 1 or 2.
Written informed consent
Exclusion Criteria:
Siewert type I esophagogastric junction tumor
Non-elective surgery
Previous gastric resection or recurrent gastric cancer
Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard van Hillegersberg, MD PhD
Organizational Affiliation
Dept. of Surgery, University Medical Center Utrecht
Official's Role
Principal Investigator
Facility Information:
Facility Name
Zorggroep Twente Almelo
City
Almelo
Country
Netherlands
Facility Name
Meander Medical Center
City
Amersfoort
Country
Netherlands
Facility Name
VU University Medical Center
City
Amsterdam
ZIP/Postal Code
1081 HZ
Country
Netherlands
Facility Name
Academic Medical Center
City
Amsterdam
ZIP/Postal Code
1105 AZ
Country
Netherlands
Facility Name
Gelre Hospital
City
Apeldoorn
Country
Netherlands
Facility Name
Catharina Hospital
City
Eindhoven
ZIP/Postal Code
5623 EJ
Country
Netherlands
Facility Name
Leiden University Medical Center
City
Leiden
ZIP/Postal Code
2333 ZA
Country
Netherlands
Facility Name
Erasmus Medical Center
City
Rotterdam
ZIP/Postal Code
3015 CE
Country
Netherlands
Facility Name
Zuyderland Medical Center
City
Sittard-Geleen
ZIP/Postal Code
6162 BG
Country
Netherlands
Facility Name
University Medical Center Utrecht
City
Utrecht
ZIP/Postal Code
3584 CX
Country
Netherlands
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual participant data that underlie the results reported in the primary manuscript will be shared after de-identification (text, tables, figures, and appendices).
IPD Sharing Time Frame
Immediately following publication; no end date.
IPD Sharing Access Criteria
Anyone who wishes to access the data for any purpose.
Citations:
PubMed Identifier
26219670
Citation
Haverkamp L, Brenkman HJ, Seesing MF, Gisbertz SS, van Berge Henegouwen MI, Luyer MD, Nieuwenhuijzen GA, Wijnhoven BP, van Lanschot JJ, de Steur WO, Hartgrink HH, Stoot JH, Hulsewe KW, Spillenaar Bilgen EJ, Rutter JE, Kouwenhoven EA, van Det MJ, van der Peet DL, Daams F, Draaisma WA, Broeders IA, van Stel HF, Lacle MM, Ruurda JP, van Hillegersberg R; LOGICA study group. Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial). BMC Cancer. 2015 Jul 29;15:556. doi: 10.1186/s12885-015-1551-z.
Results Reference
background
PubMed Identifier
34581617
Citation
van der Veen A, Brenkman HJF, Seesing MFJ, Haverkamp L, Luyer MDP, Nieuwenhuijzen GAP, Stoot JHMB, Tegels JJW, Wijnhoven BPL, Lagarde SM, de Steur WO, Hartgrink HH, Kouwenhoven EA, Wassenaar EB, Draaisma WA, Gisbertz SS, van der Peet DL, May AM, Ruurda JP, van Hillegersberg R; LOGICA Study Group. Laparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA): A Multicenter Randomized Clinical Trial. J Clin Oncol. 2021 Mar 20;39(9):978-989. doi: 10.1200/JCO.20.01540. Epub 2021 Jan 6.
Results Reference
derived
Learn more about this trial
Laparoscopic Versus Open Gastrectomy for Gastric Cancer
We'll reach out to this number within 24 hrs